<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860753</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-0922</org_study_id>
    <nct_id>NCT03860753</nct_id>
  </id_info>
  <brief_title>Effects of Pioglitazone on Stress Reactivity and Alcohol Craving</brief_title>
  <official_title>Effects of Pioglitazone on Stress Reactivity and Alcohol Craving</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of pioglitazone on stress- and
      alcohol-related measures in treatment-seeking individuals with alcohol use disorder (AUD) and
      elevated levels of stress and anxiety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in stress-reactivity as assessed by heart rate</measure>
    <time_frame>baseline, week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in stress-reactivity as assessed by systolic blood pressure</measure>
    <time_frame>baseline, week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in stress-reactivity as assessed by diastolic blood pressure</measure>
    <time_frame>baseline, week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in stress-reactivity as assessed by salivary cortisol level</measure>
    <time_frame>baseline, week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in stress-reactivity as assessed by self-report</measure>
    <time_frame>baseline, week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in alcohol use as indicated by self report</measure>
    <time_frame>baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alcohol craving as assessed by self report</measure>
    <time_frame>baseline, week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pill capsules will look same as that of active drug.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  treatment-seeking individuals diagnosed with AUD diagnostic statistical manual 5
             (DSM-5)

          -  fluent in English

          -  past month excessive alcohol use (&gt;7 drinks/week for woman, &gt;14 drinks/week for men,
             &gt;3 drinks/occasion for women&gt;4 drinks/occasion for men)14

          -  baseline Hamilton Anxiety Rating Scale (HAM-A) or Perceived Stress Scale (PSS) core
             indicative of mild to moderate anxiety (score 8 to 23) or moderate stress (score 14 to
             26), respectively

          -  increase in alcohol craving following the baseline stress reactivity assessment.

        Exclusion Criteria:

          -  Individuals will be excluded for exhibiting severe scores on the HAM-A, PSS, or
             post-traumatic (PTSD) checklist (PCL-5) at the discretion of the admitting physician

          -  physical dependence on alcohol Alcohol Use Disorders Inventory (AUDIT) score
             indicative of severe alcohol dependence (≥13 for women, ≥15 for men)

          -  greater than mild substance use disorder on drugs other than alcohol, nicotine, and
             marijuana

          -  contraindications for taking pioglitazone; medical conditions contraindicating
             pioglitazone pharmacotherapy or taking contraindicated medications

          -  be pregnant, nursing, or planning on becoming pregnant during the course of the study

          -  have any other illness, condition, or use of medications, which in the opinion of the
             PI and/or admitting physician would preclude safe and/or successful completion of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin H Yoon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin H. Yoon, PhD</last_name>
    <phone>713-486-2800</phone>
    <email>jin.ho.yoon@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas Health Science at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin H. Yoon, PhD</last_name>
      <phone>713-486-2800</phone>
      <email>jin.ho.yoon@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jin Ho Yoon</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Pioglitazone</keyword>
  <keyword>Stress</keyword>
  <keyword>Anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

